Omeros (NASDAQ:OMER) announced its earnings results on Friday. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.04), Fidelity Earnings reports. The business had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same quarter in the previous year, the business earned ($0.16) earnings per share.

Omeros stock opened at $13.02 on Friday. Omeros has a 1-year low of $8.36 and a 1-year high of $27.00.

In other news, VP Marcia S. Kelbon sold 7,529 shares of the firm’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the sale, the vice president now owns 227,645 shares of the company’s stock, valued at approximately $5,861,858.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.10% of the stock is owned by company insiders.

Several brokerages have issued reports on OMER. ValuEngine cut Omeros from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. Maxim Group reaffirmed a “buy” rating and set a $32.00 target price on shares of Omeros in a research report on Friday. HC Wainwright set a $34.00 target price on Omeros and gave the company a “buy” rating in a research report on Tuesday, July 24th. Finally, Wedbush set a $20.00 target price on Omeros and gave the company a “hold” rating in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $27.56.

ILLEGAL ACTIVITY WARNING: “Omeros (OMER) Announces Quarterly Earnings Results” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Risk Tolerance

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.